Antibody drug conjugates (ADCs) are set to play a pivotal role in the future of oncology, thanks to their potential to offer targeted treatments with a lower risk of side effects. Here, Mary Jane Hinrichs, Senior Vice President of Early Development at Ipsen, examines how ADCs could transform treatment options for tumours.
What are antibody-drug conjugates and why do they hold potential over other treatment modalities?
Antibody drug conjugates (ADCs) are an emerging technology adding significant value to the oncology treatment landscape. They are also increasingly the focus of R&D across the world and remain a modality that is regularly the focus of deals across the industry.1 As they can be highly targeted in their action, they could become the treatment of choice for clinicians and patients due to the reduced risk of side effects.1,2 This is especially important in forms of cancer where chemotherapy remains the main treatment option. Because ADCs offer a good way to specifically deliver an effective treatment to tumour systems, this could be an improvement on the systemic impact of chemotherapy.1,3
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Can’t attend live? No worries – register to receive the recording post-event.
Aside from oncology, what other indications do ADCs hold promise to treat in the future?
ADCs have seen success in haematology but there is still a lot of untapped potential in solid tumours”
ADCs have seen success in haematology but there is still a lot of untapped potential in solid tumours. In theory, ADCs could be connected to a range of different agents to target diseases affecting different organs or systems around the body. But we have only touched on their potential in oncology and there is more to do to ensure patients with challenging forms of solid tumours can benefit from ADCs, so this is the area our teams focusing on to drive progress.
What are two of the main trends in ADC development?
[The main trend in ADC development] has been an advancement in the engineering changes related to the drug to antibody ration (DAR)”
The main change has been an advancement in the engineering changes related to the drug to antibody ration (DAR). We have learned a lot from both the approved and other investigational ADCs and we can see that a higher DAR does not always mean a better or higher efficacy.2 Alongside this, we have a greater understanding of novel payloads. These have ultimately delivered successful candidates that are providing valuable therapeutics for haematological malignancies and solid tumours.2
We have also seen bispecific ADCs as a growing class of next generation ADC with enhanced specificity and improved efficacy. This class also seem to be better tolerated across patients. The potential to target more than one tumour antigen is interesting, as are the possible advantages for the patients receiving these investigational medicines.
What are the current challenges in developing ADCs?
The research and clinical communities have not yet identified how to optimise all three components of an ADC (the antibody, payload and linker) without compromising one in favour of another.3 A promising agent may not offer the optimal stability when paired with an antibody, for example, and what works for one tumour type does not always work for another.4 A recent evaluation of the ADC landscape showed that of approximately 260 ADCs in development, there are only 11 approved. This illustrates how challenging it is to strike the perfect balance to optimise all three components and create a stable ADC that can reach and act on the target cancer.2 Sharing and discussing across the community is how we will make progress together.
Ultimately, this means that we do not yet know how to translate the potential of an ADC into a real patient impact. There are many examples of where ADCs advance through early development as a strong molecule, yet when put into clinical practice that potential does not translate into a tangible patient benefit. Preclinical data can only do so much, there is more we need to uncover and understand to unlock the potential of ADCs for people with solid tumours.
How could the recent ADC-related deals within the industry impact the sector?
To truly make progress in any sector we need to unite expertise and combine forces – across industry, clinical and academia. Recent ADC deals reinforce the potential that this modality still has to improve and extend the lives of patients around the world. If we can continue to share and work together, we push further and deliver faster for patients.
What does the future of ADCs look like? How could this impact the pharmaceutical industry as a whole?
I believe the payload is the driving force of a truly ‘next generation ADC’”
I believe the payload is the driving force of a truly ‘next generation ADC’. This is what we liked about the potential for Sutro Biopharma’s ROR1 tumour antigen ADC STRO-003 as the technology maintains stability of the payload. But we also are excited by the novel payload Exatecan, which has shown significant potential in solid tumours.
About the interviewee
Mary Jane Hinrichs is Senior Vice President of Early Development at Ipsen. She leads Ipsen’s Early Development Portfolio across the company’s three therapeutic focus areas (Oncology, Rare Disease and Neuroscience). She also heads three of Ipsen’s specialised functions that support the entire pipeline from discovery through to lifecycle management. This covers nonclinical drug safety, translational and clinical pharmacology, drug metabolism and pharmacokinetics (DMPK) and pharmacometrics. Prior to joining Ipsen, she spent seven years at MedImmune (now AstraZeneca) and began her career at the US Food And Drug Administration (FDA) in the Office of Oncology Drug Products, contributing to ongoing regulatory review processes.
References
Fu et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022; 7(93)
Maecker et al. Exploration of the antibody–drug conjugate clinical landscape. Mabs.2023;15(1)
Shastry et al. Rise of Antibody-Drug Conjugates: The Present and Future. ASCO Educational Book. 2023; 3
Tsuchikama et al. Exploring the next generation of antibody–drug conjugates. Nat. Rev. Clin. Oncol.2024; 21 203–223
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.